We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Boston Scientific (BSX) Beats on Earnings & Revenues in Q4
Read MoreHide Full Article
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm Management, Cardiovascular and MedSurg.
Currently, Boston Scientific has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings:The Zacks Consensus Estimate remained steady at 29 cents per share over the last 30 days. Boston Scientific’s adjusted earnings of 30 cents per share has beaten the Zacks Consensus Estimate by 3.4%.
Full year adjusted earnings came in at $1.11 per share which has also surpassed the Zacks Consensus Estimate of $1.10 by 0.9%.
Boston Scientific Corporation Price and EPS Surprise
Revenues:Boston Scientific posted revenues of $2.19 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.16 billion.
Full year revenues came in at $8.38 billion which has also outpaced the Zacks Consensus Estimate of $8.36 billion.
Key Stats: In the fourth-quarter 2016, Boston Scientific’s Cardiovascular segment revenues increased 11% at Constant exchange rate (CER) to $840 million, while Rhythm Management segment’s revenue grew 7% at CER with the revenue amounting to $536 million. On the other hand, revenues from MedSurg segment improved 13% at CER to $815 million.
Major Factors: Boston Scientific has posted impressive fourth quarter results by delivering revenue growth in all regions and across all segments. Moreover, during the reported quarter, management announced positive results from the 900-patient MultiSENSE study evaluating the performance of the HeartLogic Heart Failure Diagnostic Service to predict impending heart failure (HF) decompensation in a late-breaking clinical trial session at the American Heart Association Scientific Sessions 2016.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Boston Scientific earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Boston Scientific (BSX) Beats on Earnings & Revenues in Q4
MA-based Boston Scientific Corporation (BSX - Free Report) is a leading global manufacturer of medical devices that are used in a wide range of interventional medical specialties. Boston Scientific technologies address a wide range of health conditions through 7 business units that are organized into 3 global reporting segments: Rhythm Management, Cardiovascular and MedSurg.
Currently, Boston Scientific has a Zacks Rank #3 (Hold) but that could change following its fourth-quarter 2016 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.) We have highlighted some of the key details from the just-released announcement below:
Earnings:The Zacks Consensus Estimate remained steady at 29 cents per share over the last 30 days. Boston Scientific’s adjusted earnings of 30 cents per share has beaten the Zacks Consensus Estimate by 3.4%.
Full year adjusted earnings came in at $1.11 per share which has also surpassed the Zacks Consensus Estimate of $1.10 by 0.9%.
Boston Scientific Corporation Price and EPS Surprise
Boston Scientific Corporation Price and EPS Surprise | Boston Scientific Corporation Quote
Revenues:Boston Scientific posted revenues of $2.19 billion, comfortably beating the Zacks Consensus Estimate for revenues of $2.16 billion.
Full year revenues came in at $8.38 billion which has also outpaced the Zacks Consensus Estimate of $8.36 billion.
Key Stats: In the fourth-quarter 2016, Boston Scientific’s Cardiovascular segment revenues increased 11% at Constant exchange rate (CER) to $840 million, while Rhythm Management segment’s revenue grew 7% at CER with the revenue amounting to $536 million. On the other hand, revenues from MedSurg segment improved 13% at CER to $815 million.
Major Factors: Boston Scientific has posted impressive fourth quarter results by delivering revenue growth in all regions and across all segments. Moreover, during the reported quarter, management announced positive results from the 900-patient MultiSENSE study evaluating the performance of the HeartLogic Heart Failure Diagnostic Service to predict impending heart failure (HF) decompensation in a late-breaking clinical trial session at the American Heart Association Scientific Sessions 2016.
Stock Price: Following the earnings release, share prices did not show any movement in the pre-market trading session.
Check back later for our full write up on this Boston Scientific earnings report later!
Zacks’ Best Private Investment Ideas
While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.
Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>